The U.S. next generation sequencing sector was valued at USD 3.3 billion in 2026 and is projected to reach USD 12.52 billion by 2035, expanding at a 15.95% CAGR from 2026 to 2035.
Key Highlights
- Sequencing instruments held the leading product share at 35% in 2025.
- Consumables and reagents are expected to record the fastest growth.
- Clinical diagnostics accounted for 40% of revenue in 2025.
- Drug discovery and development is projected to expand rapidly.
- Hospitals and diagnostic laboratories led end users with 45% share.
- Whole genome sequencing represented 30% of sequencing types.
- Sequencing by synthesis held the largest technology share at 50%.
What Is Driving Growth?
Next-generation sequencing (NGS) enables rapid, high-throughput analysis of DNA and RNA. Its growing use in precision medicine, cancer research, rare disease diagnosis, infectious disease surveillance, and drug development is supporting continued adoption across the United States.
Declining sequencing costs, improved bioinformatics, automation, and growing genomic datasets are also creating new opportunities. Artificial intelligence is increasingly being integrated into NGS workflows to automate processes, improve variant detection, and accelerate genomic data interpretation.
AI and NGS
AI and machine learning are transforming sequencing workflows by helping researchers analyze large datasets, identify genetic variants, discover biomarkers, and optimize experimental processes. Cloud-based bioinformatics and automated sample preparation are further improving efficiency and reducing manual intervention.
Government Support
Government initiatives are strengthening genomic research. In June 2026, the NIH expanded its All of Us Research Program, releasing genomic and health data from more than 747,000 participants. In April 2026, the FDA issued draft guidance recommending NGS-based methods for evaluating genome-editing therapies.
Segment Insights
Clinical diagnostics: Led with 40% share in 2025, supported by growing demand for genetic testing, early diagnosis, and personalized treatment.
Hospitals and diagnostic laboratories: Held 45% share as healthcare providers increasingly adopt advanced genomic technologies.
Whole genome sequencing: Accounted for 30% share, supporting rare disease research, cancer analysis, and population genomics.
Sequencing by synthesis: Dominated technology with 50% share because of its accuracy, scalability, and high-throughput capabilities.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/6450
Outlook
The U.S. NGS sector is positioned for strong expansion as precision medicine, AI-powered analysis, clinical genomics, liquid biopsy, pharmacogenomics, and multi-omics applications continue developing. Rising research investments and technological innovation are expected to further strengthen adoption through 2035.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium